ACE inhibitors in elderly patients with hypertension: Special considerations

Drugs and Aging

Volumn 8, Issue 1, 1996, Pages 29-37

  Ravid, M ^a   Ravid, D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; NIFEDIPINE; NITRATE; SPIRAPRIL; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; VERAPAMIL;

AGED; ATHEROSCLEROSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MORBIDITY; PRIORITY JOURNAL; REVIEW; SURVIVAL;

EID: 0030032182     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608010-00006     Document Type: Review

References (89)

1. Schappert SM. National ambulatory medical care survey from vital and health statistics for the centers for disease control and prevention. National Center for Health Statistics. Advance Data 1993; 230: 1-20
2. Abrams WB. Pathophysiology of hypertension in older patients. Am J Med 1988; 85 Suppl. B: 7-13
3. Applegate WB. Hypertension in elderly patients. Ann Intern Med 1989; 110: 901-15
4. Kannel WB, Castelli WP, McNamara PM, et al. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 1972; 287: 781-7
5. Shekelle RB, Ostfeld AM, Klawans HL. Hypertension and risk of stroke in an elderly population. Stroke 1974; 5: 71-5
6. Veterans Administration Cooperative Study Group on AntiHypertensive Agents. Low dose captopril for the treatment of mild to moderate hypertension. Results of a 14 week trial. Arch Intern Med 1984; 144: 1947-53
7. Kannel WB, Gordon T. Evaluation of cardiovascular risk in the elderly. The Framingham study. Bull NY Acad Med 1978; 54: 573-91
8. Holmes I, Waaler HT. Five year mortality in the city of Bergen, Norway, according to age, sex and blood pressure. Acta Med Scand 1976; 200: 229-39
9. Svarolsudd K, Tibbin G. Mortality and morbidity during 13.5 years follow-up in relation to blood pressure. Acta Med Scand 1979; 205: 483-92
10. Borhani WO. Prevalence and prognostic significance of hypertension in the elderly. J Am Geriatr Soc 1986; 34: 112-4
11. Kannel WB, Wolf PA, McGee DL. Systolic blood pressure, arterial rigidity and risk of stroke. The Framingham study. JAMA 1981; 245: 1225-9
12. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham heart study. JAMA 1994; 272: 33-6
13. Weber MA, Neutel JM, Cheung DG. Hypertension in the aged: a pathophysiologic basis for treatment. Am J Cardiol 1989; 63: 25H-32H
14. Schnaper HW. Angiotensin-converting enzyme inhibitors for systemic hypertension in young and elderly patients. Am J Cardiol 1992; 69: 54C-58C
15. Messerli FH, Ventura OH, Glade BL. Essential hypertension in the elderly: hemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983; 2: 983-5
16. Hulley SB, Farberg CD, Garland B, et al. For the SHEP research group. Systolic hypertension in the elderly. Program: antihypertensive efficacy of chlorthalidone. Am J Cardiol 1985; 56: 913-20
17. Amery A, Brixko P, Clement D, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; 1: 1349-54
18. Kligman EW, Highbee MD. Drug therapy for hypertension in the elderly. J Fam Pract 1989; 28: 81-7
19. Materson BJ, Reda DJ, Cushman WC, et al. Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21
20. Ravid M, Lang R, Jutrin I. The relative antihypertensive potency of propanolol, oxprenolol, atenolol and metoprolol given once daily - a double-blind, crossover, placebo controlled study in ambulatory patients. Arch Intern Med 1985; 145: 1321-3
21. Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of beta blockers. Arch Intern Med 1989; 149: 514-5
22. Joint National Committee. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC-V). Arch Intern Med 1993; 153: 154-83
23. Ferrarra LA, Di Marino L, Russo O, et al Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. Hypertension 1993; 21: 97-104
24. Guthrie R. The treatment of concomitant hypertension and prostatic obstructive symptoms with terazosin [abstract]. Am J Hypertens 1993; 6: 127A
25. Amadeo C, Korbin I, Ventura OH. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation 1986; 73: 108-13
26. Schmeider RE, Messerli FH, Gravaglia GE. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987; 75: 1030-6
27. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists. Clin Pharmacokinet 1992; 22: 416-33
28. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotcnsive diabetic patients with microalbuminuria. BMJ 1991; 302: 210-6
29. Menard J. Improving hypertension treatment. Where should we put our efforts: new drugs, new concepts, or new management. Am J Hypertens 1992; 5 Suppl.: 252S-258S
30. Tesia MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. N Engl J Med 1993; 328: 907-13
31. Grosskopf S, German R, Beillin LJ, et al. A randomized double blind comparison of enalapril versus hydrochlorothiazide in elderly hypertensives. J Hum Hypertens 1989; 3: 131-6
32. Weir MR, Weber MA, Punzi HA, et al. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens 1992; 6: 133-8
33. Reid IA. Interactions between Ang II, sympathetic nervous system and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 25: E763-E778
34. Gomez HJ, Smith SG, Moncloa F. Efficacy and safety of lisinopril in older patients with essential hypertension. Am J Med 1988; 85: 35-7
35. Egan BM, Fleissner MJ, Stepniakowski K, et al. Improved baroreflex sensitivity in elderly hypertensives on lisinopril is not explained by blood pressure reduction alone. J Hypertens 1993; 11: 1113-20
36. Millar JA, Derkx FHM, McLean R, et al. Pharmacodynamics of converting enzyme inhibitors: cardiovascular, endocrine, and autonomie effects of enalapril and MR531. Br J Clin Pharmacol 1986; 14: 347-55
37. Aiayi AA, Campbell BC, Howie CA, et al. Acute and chronic-effects of converting enzyme inhibitors, enalapril and lisinopril on reflex control of heart rate in normotensive men. J Hypertens 1985; 3: 47-53
38. Garst JB, Koletsky S, Wisenbaugh PE, et al. Arterial wall renin and renal venous renin in the hypertensive rat. Clin Sci 1979; 56: 41-6
39. Cushman DW, Wang FL, Fung WC, et al. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294-306
40. Caretero OA, Myazaki S, Scicle AG. Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor captopril. Hypertension 1981; 3: 18-22
41. Linz W, Scholkens BA. Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts. J Cardiovasc Pharmacol 1987; 10 (Suppl. 7): 575-82
42. Wang DH, Pawitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 1990; 15: 68-77
43. Nakamura M, Funakoshi T, Yoshida H, et al. Endothelium-dependent vasodilatation is augmented by angiotensin-converting enzyme inhibitors in healthy volunteers. J Cardiovasc Pharmacol 1992; 20: 949-54
44. Hirooka Y, Imaizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependenl vasodilatation in hypertensive patients. Hypertension 1992; 20: 175-80
45. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin-converting enzyme inhibitor enalapril on the long term progression of left ventricular dysfunction in patients with heart failure Circulation 1992; 86: 431-8
46. Lindpaintner R, Garten D. The cardiac renin angiotensin system: an appraisal of current experimental and clinical evidence. Circ Res 1991; 68: 905-21
47. Haber HL, Powers ER, Gimple LW, et al. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation 1994; 89: 2616-25
48. Gonzales-Fernandez RA, Altieri PI, Fernandez-Martinez J, et al. Prevalence of ventricular arrhythmias after left ventricular mass regression in the elderly. Cardiol Elderly 1993; 1: 185-90
49. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 1992; 340: 1173-8
50. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77
51. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71: 602-4
52. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. Hypertension 1994; 23: 275-85
53. Katz RJ, Levy WS, Buff L, et al. Prevention of nitrate tolerance with angiotensin-converting enzyme inhibitors. Circulation 1991; 83: 1271-7
54. Torup M, Waldemar G, Paulson OB. Ceranapril and cerebral blood flow autoregulation. J Hypertens 1993; 11: 399-405
55. Laher MS. Lisinopril in elderly patients with hypertension. Drugs 1990; 39 Suppl. 2: 55-63
56. Reid JL, Macdonald NJ, Lees KR, et al. Angiotensin convening enzyme inhibitors in the elderly. Am Heart J 1989; 117: 751-5
57. Horrath JS, Waagh RC, Tiller DJ, et al. The detection of renovascular hypertension: a study of 490 patients by renal angiography. Q J Med 1982; 51: 139-46
58. Brunner HR. ACE inhibitors in renal disease. Kidney Int 1992; 42: 463-79
59. Textor SG. ACE inhibitors in renovascular hypertension. Cardiovasc Drugs Ther 1990; 4: 229-35
60. Hollenberg NK. Hypertension in an aging population: problems and opportunities. Am J Med 1991; 90 Suppl. 4B: 1-2
61. Kalra PA, Mamtora H, Holmes AM, et al. Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Q J Med 1990; 77: 1013-8
62. Knecht A, Grossman E, Rosenthal T. Enalapril in the treatment of renovascular hypertension. Clin Exp Hypertens 1985; A7 (10): 1371-93
63. Fluck RJ, Raine AEG. ACE inhibitors in non diabetic renal disease. Br Heart J 1994; Suppl. 72: 46-51
64. Pettinger WA, Lee HC, Reisch J, et al. Long-term improvement in renal function after short term blood pressure control in hypertensive nephrosclerosis. Hypertension 1989; 13: 766-72
65. Wight JP, Brown CB, Nahas AM. Effect of control of hypertension on progressive renal failure. Clin Nephrol 1993; 39: 305-11
66. Ruliope LM, Miranda B, Morales JM, et al. Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 1989; 13: 120-6
67. Bohler J, Woitas R, Keller E, et al. Effect of nifedipine and captopril on glomerular hyperfiltration in normotensive men. Am J Kidney Dis 1992; 20: 132-9
68. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in type II diabetic patients. Ann Intern Med 1993; 118: 577-81
69. Brunner FP, Thiel G, Hermle M, et al. Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1989; 36: 969-77
70. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685-8
71. Biorck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43
72. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
73. Jenkins AC, Knill JR, Dreslinski GR. Captopril in the treatment of the elderly hypertensive patients. Arch Intern Med 1985; 145: 2029-31
74. Paul M, Bachmann J, Ganten D. The tissue renin-angiotensin system in cardiovascular disease. Trends Cardiovasc Med 1992; 2: 94-9
75. Herman AG. Differences in structure of angiotensin-converting enzyme inhibitors might predict differences in action. Am J Cardiol 1992; 70: 102C-108C
76. Towsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150: 1175-83
77. Andreoli SP. Captopril scavenges hydrogen peroxide and reduces, but does not eliminate oxidant-induced cell injury. Am J Physiol 1993; 264: F120-F127
78. Liu X, Engelman RM, Rousou JA, et al. Attenuation of myocardial reperfusion injury by sulphydryl-containing angiotensin-converting enzyme inhibitors. Cardiovasc Drugs Ther 1992; 6: 437-43
79. Ravid D, Lishner M, Lang R, et al. Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure. J Clin Pharmacol 1994; 34: 1116-20
80. Postma CT, Dennesen PJW, de Boo T, et al. First dose hypotension after captopril; can it be predicted. A study of 240 patients. J Hum Hypertens 1992; 6: 205-9
81. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med 1983; 308: 373-6
82. Toto RD, Mitchell HC, Lee HC, et al Reversible renal insufficiency due to angiotensin-converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991; 115: 513-9
83. Israeli ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-42
84. Reisin L, Schneeweiss A. Spontaneous disappearance of cough induced by angiotensin converting enzyme inhibitors (captopril or enalapril). Am J Cardiol 1992; 70: 398-9
85. Fogari R, Zoppi A, Tettamanti F, et al. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomised cross-over study. J Cardiovasc Pharmacol 1992; 19: 670-3
86. Bulpitt CJ, Fletcher AE. Cognitive function and angiotensinconverting enzyme inhibitors in comparison with other antihypertensive drugs. J Cardiovasc Pharmacol 1992; 19 Suppl. 6:S100-S104
87. Paolisso G, Gambardella A, Verza M, et al. ACE inhibition improves insulin-sensitivity in aged insulin resistant hypertensive patients. J Hum Hypertens 1992; 6: 175-9
88. Keilani T, Schlueter WA, Levin MI, et al. Improvement of lipid abnormalities associated with proteinuria using fosinopril an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993; 118: 246-54
89. Ravid M, Neuman L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: the effect of angiotensin converting enzyme inhibitors. Kidney Int 1995; 47: 907-10